How to Appeal a Wegovy (Semaglutide) Denial from Cigna
Denied Wegovy? It is FDA-approved for chronic weight management and for reducing cardiovascular risk in adults with heart disease and obesity — and that heart-health indication is a powerful, underused appeal angle.
Why Wegovy (semaglutide) claims get denied
- Formulary exclusion — some plans exclude weight-loss drugs entirely (check this first, below)
- Step therapy — try a different agent first
- BMI or comorbidity criteria not documented
- Framed as "cosmetic" rather than medical
The argument that wins
- Use the cardiovascular indication: Wegovy is FDA-approved to reduce the risk of major cardiovascular events (heart attack, stroke) in adults with established cardiovascular disease and obesity or overweight. If you have heart disease, this is medical necessity well beyond weight.
- Document your comorbidities — prediabetes, hypertension, high cholesterol — to support medical necessity.
- Request a step-therapy exception if the plan requires another drug first and there is a clinical reason it is inappropriate for you.
Evidence to gather
- Your BMI and weight history
- Documentation of established cardiovascular disease, if applicable
- Comorbidity documentation: A1c, blood pressure, lipid panel
- Records of prior weight-loss drugs tried and their outcomes
- A letter of medical necessity from your prescriber
Appealing with Cigna
Cigna appeals are typically submitted through the myCigna portal or by mail to the address on your Explanation of Benefits. The standard internal appeal window is generally 180 days, with expedited review for urgent needs.
Whatever the channel, the argument is what wins — and that is the same regardless of insurer. Use the grounds above, attach the evidence, and file before your deadline.
Related appeal guides
Want this done for you?
Run a free case check — we read your denial, tell you if it’s appealable, and only charge ($149 flat) if it is. Expert-reviewed appeal in 2 business days.
Check my denial — freeFrequently asked questions
I have heart disease — does that strengthen my Wegovy appeal?
Yes. Wegovy is FDA-approved to reduce cardiovascular events in adults with established heart disease and obesity or overweight. Documenting your cardiac history reframes the request as cardiovascular risk reduction, not weight loss alone.
My plan excludes weight-loss drugs — can I still appeal?
A blanket weight-loss exclusion generally cannot be overturned on medical necessity. But if you qualify under the cardiovascular indication, that may fall outside a pure weight-loss exclusion — worth checking. Our free case check reviews this.